Limits...
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH - Oncotarget (2015)

Bottom Line: The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis.Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS.The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

ABSTRACT
The hormone receptor (HR) status and human epidermal growth hormone receptor 2 (HER2) status of patients with breast cancer may change following neoadjuvant chemotherapy (NCT). This prospective observational study aimed to evaluate the prognostic impact of receptor conversion in breast cancer patients treated with NCT.Of the 423 consecutive patients who had residual disease in the breast after NCT, 55 (13.0%) changed from HR (+) to HR (-), 23 (5.4%) changed from HR (-) to HR (+), 27 (6.4%) changed from HER2 (+) to HER2 (-), and 13 (3.1%) changed from HER2 (-) to HER2 (+). A total of 54 (12.8%) changed to the triple-negative (TN) tumor phenotype. The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis. Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS. In conclusion, patients with breast cancer may experience changes in HR status, HER2 status and tumor phenotype after NCT. The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

No MeSH data available.


Related in: MedlinePlus

Comparison of Ki-67 expression in the different conversion groupsThe data represent the mean ± standard deviation of Ki67 levels. Statistical significance is indicated.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496242&req=5

Figure 1: Comparison of Ki-67 expression in the different conversion groupsThe data represent the mean ± standard deviation of Ki67 levels. Statistical significance is indicated.

Mentions: We also compared the expression of Ki67 in different receptor conversion groups. Significantly high Ki67 expression was observed in the groups with loss of HR status (mean, 39.0), loss of HER2 status (mean, 36.5) and a discordant triple-negative (TN) tumor phenotype (mean, 30.2) (Figure 1).


Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH - Oncotarget (2015)

Comparison of Ki-67 expression in the different conversion groupsThe data represent the mean ± standard deviation of Ki67 levels. Statistical significance is indicated.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496242&req=5

Figure 1: Comparison of Ki-67 expression in the different conversion groupsThe data represent the mean ± standard deviation of Ki67 levels. Statistical significance is indicated.
Mentions: We also compared the expression of Ki67 in different receptor conversion groups. Significantly high Ki67 expression was observed in the groups with loss of HR status (mean, 39.0), loss of HER2 status (mean, 36.5) and a discordant triple-negative (TN) tumor phenotype (mean, 30.2) (Figure 1).

Bottom Line: The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis.Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS.The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

View Article: PubMed Central - PubMed

Affiliation: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

ABSTRACT
The hormone receptor (HR) status and human epidermal growth hormone receptor 2 (HER2) status of patients with breast cancer may change following neoadjuvant chemotherapy (NCT). This prospective observational study aimed to evaluate the prognostic impact of receptor conversion in breast cancer patients treated with NCT.Of the 423 consecutive patients who had residual disease in the breast after NCT, 55 (13.0%) changed from HR (+) to HR (-), 23 (5.4%) changed from HR (-) to HR (+), 27 (6.4%) changed from HER2 (+) to HER2 (-), and 13 (3.1%) changed from HER2 (-) to HER2 (+). A total of 54 (12.8%) changed to the triple-negative (TN) tumor phenotype. The loss of HR positivity was an independent prognostic factor for worse disease-free survival (DFS) and worse overall survival (OS) in multivariate survival analysis. Furthermore, the switch to the TN phenotype after NCT was another independent prognostic factor for worse survival for both DFS and OS. In conclusion, patients with breast cancer may experience changes in HR status, HER2 status and tumor phenotype after NCT. The loss of HR positivity and the switch to the TN phenotype after NCT were associated with a worse patient outcome.

No MeSH data available.


Related in: MedlinePlus